Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GLSI
GLSI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GLSI News
Greenwich LifeSciences Reports Promising Phase 3 Trial Data for GLSI-100
Mar 17 2026
NASDAQ.COM
Greenwich LifeSciences Shares Surge 13% on Positive Immunotherapy Trial Results
Mar 17 2026
stocktwits
Greenwich LifeSciences Updates on FLAMINGO-01 Trial Progress
Mar 17 2026
Yahoo Finance
Greenwich LifeSciences Accelerates Clinical Trial Screening Rate
Mar 03 2026
NASDAQ.COM
Greenwich LifeSciences Updates on Clinical Trial Progress
Mar 03 2026
Newsfilter
Greenwich LifeSciences Announces AACR Abstracts for FLAMINGO-01
Feb 24 2026
Newsfilter
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
Jan 30 2026
PRnewswire
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
Jan 30 2026
Newsfilter
Sarepta Therapeutics Reports Significant Three-Year Study Results
Jan 26 2026
Benzinga
Greenwich LifeSciences (GLSI) Gains FDA Approval for GP2, Stock Rises 27.8%
Jan 22 2026
Benzinga
Greenwich LifeSciences (GLSI) Receives FDA Approval for First Commercial GP2 Lot in Phase 3 Trial
Jan 22 2026
NASDAQ.COM
Greenwich LifeSciences (GLSI) Gains 33% After FDA Approves First Commercial Lot of GP2 for Late-Stage Trial
Jan 22 2026
seekingalpha
Greenwich LifeSciences (GLSI) Secures FDA Clearance, Stock Rises Over 16%
Jan 22 2026
stocktwits
Greenwich LifeSciences Receives FDA Approval for First Commercial Lot of GP2
Jan 22 2026
Newsfilter
Oncolytics Biotech Inc. Reports 33% Response Rate for Pelareorep in Colorectal Cancer
Jan 07 2026
Newsfilter
Oncolytics Biotech's Immunotherapy Shows Significant Improvement in Cancer Treatment Outcomes
Jan 07 2026
PRnewswire
Show More News
